Global Corporate Affairs Archives | Page 101 of 1088 | Be Korea-savvy

Archive by category Global Corporate Affairs

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

VANCOUVER, British Columbia, Aug. 11, 2025 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointments of Greg Ciongoli and Robert E. Landry to the Company’s Board of Directors, [...]

CGTN: ‘Dongji Rescue’: Humanity forged in blood and fire

CGTN: ‘Dongji Rescue’: Humanity forged in blood and fire

BEIJING, Aug. 10, 2025 (Korea Bizwire) – The film “Dongji Rescue,” based on the 1942 sinking of the Japanese ship Lisbon Maru after it was torpedoed by American forces, is the moving story of Chinese fishermen from nearby Dongji Island courageously rescuing the over 1800 British POWs aboard the liner despite Japanese soldiers’ firing. It’s [...]

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK media.  HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 75% (N=71), as demonstrated in the Beamion-LUNG 1 clinical trial1  Accelerated approval follows Priority Review and Breakthrough Therapy Designation granted by the U.S. FDA for the treatment of patients with HER2 (ERBB2)-mutant advanced non-small cell [...]

The Go-No-Go (GNG) Machine is Named by DUPR, Pickleballtournaments.com and The UPA-A as the Official and Exclusive On-Site Deflection Testing Device for Professional and Amateur Tours Across the Globe

The Go-No-Go (GNG) Machine is Named by DUPR, Pickleballtournaments.com and The UPA-A as the Official and Exclusive On-Site Deflection Testing Device for Professional and Amateur Tours Across the Globe

BOCA RATON, Fla., Aug. 08, 2025 (Korea Bizwire) – The Go-No-Go (GNG) Machine has been officially named the exclusive on-site paddle deflection testing device for professional and amateur pickleball by three major platforms: Dynamic Universal Pickleball Rating (DUPR), the United Pickleball Association of America (UPA-A), and Pickleballtournaments.com .This designation marks a pivotal advancement in the [...]

Yachting: Five years of sustainable innovation at Yacht Club de Monaco, Rendezvous set for September 21-22

Yachting: Five years of sustainable innovation at Yacht Club de Monaco, Rendezvous set for September 21-22

MONACO, Aug. 08, 2025 (Korea Bizwire) – Back for its fifth edition, the Monaco Smart & Sustainable Marina Rendezvous, returns on 21 and 22 September to bring together the leaders of maritime sustainability. Launched in 2021 and organised by M3 Monaco with the support of the Prince Albert II Foundation and the Yacht Club de Monaco, the event [...]

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

SHANGHAI, Aug. 08, 2025 (Korea Bizwire) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application (“sNDA”) for toripalimab (trade name: TUOYI®) in combination with disitamab vedotin, an antibody-drug conjugate (“ADC”) [...]

First LLM with Infinite Context Attention is here, wiping out $1.2 billion RAG market value by allowing AI to live outside the Matrix

First LLM with Infinite Context Attention is here, wiping out $1.2 billion RAG market value by allowing AI to live outside the Matrix

SAN FRANCISCO, Aug. 07, 2025 (Korea Bizwire) – Silicon Valley startup, iFrame™ AI, has quietly secured a nearly $20 million deal with a leading cloud provider to launch the world’s first Large Attention Model with an infinite context window – a breakthrough poised to disrupt the professional services industry and undercut OpenAI-like companies’ revenue from costly, [...]

TYLin Group Announces Strategic Leadership Appointment – Jenni Roseleip as Chief Marketing Officer

TYLin Group Announces Strategic Leadership Appointment – Jenni Roseleip as Chief Marketing Officer

Boston, MA, Aug. 07, 2025 (Korea Bizwire) – TYLin Group, a global leader in planning, advisory, and engineering services, and a leading infrastructure brand within Sidara, proudly announces the appointment of Jenni Roseleip as its new Chief Marketing Officer. Jenni assumes a pivotal leadership role within the organization’s Global Executive Committee.   Jenni brings over two [...]

WeightWatchers Appoints SoulCycle Co-Founder Julie Rice as Chief Experience Officer to Lead Community and Brand Innovation

WeightWatchers Appoints SoulCycle Co-Founder Julie Rice as Chief Experience Officer to Lead Community and Brand Innovation

NEW YORK, Aug. 07, 2025 (Korea Bizwire) – WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced that longserving WW board member Julie Rice, the entrepreneur and brand builder best known for co-founding SoulCycle, is joining WeightWatchers as Chief Experience Officer. As WeightWatchers evolves its holistic [...]

Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia

Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia

CT-155 showed a reduction in experiential negative symptoms as an adjunct to standard of care antipsychotic therapy from baseline to week 16, as measured by CAINS-MAP. CT-155 is an investigational prescription digital therapeutic being evaluated to target negative symptoms of schizophrenia in a registrational randomized clinical trial.1,2 Often underappreciated and less recognized, negative symptoms impact [...]